MilliporeSigma News
-
MilliporeSigma Invests $76 Million To Expand ADC Manufacturing For Novel Cancer Therapies
11/6/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced a $76 million expansion of its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri. This investment will triple existing capacity and enhance the company’s contract development and manufacturing organization (CDMO) offering, reinforcing its commitment to clients and patients.
-
MilliporeSigma Announces Siren Biotechnology As Winner Of Its North American Advance Biotech Grant
6/4/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced today that Siren Biotechnology has been selected as the North American winner of its 13th Advance Biotech Grant Program. The biotechnology startup, which is headquartered in San Francisco, California, USA, was selected for the development of its universal adeno-associated virus (AAV) immuno-gene therapy for cancer.
-
MilliporeSigma Expands Its Optimized VirusExpress® Platform For Lentiviral Vectors, Further Enhancing Quality And De-Risking Cell And Gene Therapy Manufacturing
5/8/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, is pleased to announce the expansion of its VirusExpress® platform used in the development and manufacturing of lentiviral vectors.
-
MilliporeSigma Announces Support Of SaudiVax In Becoming First Developer And Manufacturer Of Halal Vaccines And Biotherapeutics In Saudi Arabia
3/18/2022
MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that the Life Science business sector will support SaudiVax Ltd., based in the Kingdom of Saudi Arabia, to design a best-in-class, multi-modality manufacturing facility to localize manufacturing of biologics and vaccines for the MENA region.
-
MilliporeSigma To Manufacture Next-Generation Biotherapeutics For Alteogen
3/18/2022
MilliporeSigma announced an agreement with Alteogen, Inc., of South Korea, providing late-stage CDMO services through MilliporeSigma’s BioReliance® End-to-End Solutions. Alteogen selected MilliporeSigma to develop and produce recombinant biologics for the development and clinical evaluation of next-generation therapeutics of monoclonal antibody drugs.
-
MilliporeSigma Announces Organizational Transformation To Strengthen CDMO Offering And Accelerate Future Growth
3/18/2022
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced several organizational changes and a new operating model to support the long-term growth strategy of the Life Science business sector and to better serve the evolving needs of its global customers.
-
MilliporeSigma Advances Bioprocessing Capabilities With Raman Technology Sensor Acquisition
7/1/2020
Merck, a leading science and technology company, today enhanced its advanced bioprocess portfolio through the acquisition of RESOLUTION Spectra Systems, a Meylan, France-based leader in bioprocess analytical monitoring.
-
MilliporeSigma Accelerates Readiness Of Bioprocessing Facility Of The Future
4/30/2020
MilliporeSigma today unveiled the next component of its BioContinuum™ Platform, the Bio4C™ Software Suite, creating a first-of-its-kind ecosystem that combines process control, analytics and plant-level automation. This transformative software suite will allow users to look across the entire manufacturing process versus individual operational units, giving biomanufacturers complete process control and deep insights, bringing Bioprocessing 4.0 to the here and now.